|  |  |  |  |
| --- | --- | --- | --- |
| **Table 1 baseline characteristics and treatment in all patients** | | | |
| **Baseline characteristics** | **Total**  **(N=102)** | **Treatment and outcome** | **Total**  **(N=102)** |
| Age ≥60 (years) | 22 (22.6%) | **Time (days)** |  |
| Gender (Men) | 54 (52.9%) | Onset to admission | 5 (3-7) |
| Smoker | 11 (10.8%) | Onset to discharge | 16 (14-23) |
| Drink | 17 (16.7%) | Hospital stays | 12 (10-15) |
| **Exposure history** |  | **Treatment** |  |
| Exposure to infected patient | 100 (98.0%) | Low flow oxygen  High flow oxygen | 89 (87.2%)  8 (7.8%) |
| Unknown exposure | 2 (2.0%) | Invasive mechanical ventilation | 6 (5.9%) |
| Family aggregation | 15 (14.7%) | CRRT | 5 (4.9%) |
| **Underlying diseases** |  | ECMO | 1 (1.0%) |
| Hypertension | 14 (14.3%) | Antiviral treatment | 88 (86.3%) |
| Diabetes | 8 (8.2%) | Antibiotic treatment | 22 (21.6%) |
| COPD | 4 (4.1%) | Glucocorticoids | 4 (3.9%) |
| CVD | 8 (8.2%) | Chinese medicinal therapy | 60 (58.8%) |
| CKD | 4 (4.1%) | Interferon | 87 (85.3%) |
| **Symptoms** |  | Human Albumin | 8 (7.8%) |
| Fever | 90 (87.3%) | **Clinical outcome** |  |
| Cough | 75 (73.5%) | ICU | 16 (15.7%) |
| Fatigue | 23 (22.5%) | Discharged | 98 (96.1%) |
| Myalgia | 17 (16.7%) | Death | 4 (3.9%) |

Note: Data are n (%). where N is the total number of patients with available data.

Abbreviations: COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease;

CKD, chronic kidney disease; CRRT, continuous renal replacement therapy;

ECMO, Extracorporeal membrane oxygenation; ICU, intensive care unit.